Persistent URL of this record https://hdl.handle.net/1887/98655
In Collections
This item can be found in the following collections:
![Dose-Response Effects Of Denosumab, a Novel Subcutaneous RANKL Inhibitor, On The Progression Of Bone Erosion In Japanese Patients With Rheumatoid Arthritis Treated With Methotrexate: Results Of Phase II DRIVE Study-A Twelve Month Placebo Controlled, Rando](https://scholarlypublications.universiteitleiden.nl/sites/all/themes/scholarly/img/closed_access.png)
Dose-Response Effects Of Denosumab, a Novel Subcutaneous RANKL Inhibitor, On The Progression Of Bone Erosion In Japanese Patients With Rheumatoid Arthritis Treated With Methotrexate: Results Of Phase II DRIVE Study-A Twelve Month Placebo Controlled, Randomized, Double Blind Study
- All authors
- Takeuchi, T.; Tanaka, Y.; Ishiguro, N.; Yamanaka, H.; Yoneda, T.; Genant, H.K.; Heijde, D. van der
- Date
- 2013-10-31
- Journal
- Arthritis and Rheumatism
- Volume
- 65
- Pages
- S1198 - S1198